Regardless of one's individual perspective, those (to say the least) are intriguing numbers.
The great thing is, apart from the converting options, I can't see any more dilutionary impact on the SP (none whatsoever on the horizon).
As management themselves have stated, all funding until Phase III is locked away.
Then it becomes a matter of commercialisation - by which time at least one Big Pharma (if logic dictates) will be well and truly on board.
Insert here the most likely candidate: Cephalon, Dendreon, CSL ......?
No matter ...... an SP of 31 cents as of today will represent a mere footnote in the future historical pages of our very own cancer slayer cum millionaire-maker:
PRIMA BIOMED
Institutionally owned, Big Pharma backed, Nobel Prizes to PRR's think-tank, billions upon billions of export dollars, dividend income streams to rival CSL.
PRR Price at posting:
25.9¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)